November 12, 2012 15:08
FAS green-lights AFK Sistema bid to buy 100% of VeroPharm, but with terms (Part 2)
MOSCOW. Nov 12 (Interfax) - Russia's Federal Antimonopoly Service (FAS) has approved AFK Sistema's (RTS: AFKS) request for permission to buy 100% of the stock in pharmaceuticals company OJSC VeroPharm (RTS: VRPH), but has attached some terms, a FAS statement says.
The FAS established that VeroPharm has a dominating position on the market for medicines with MNN Gemifloksatsin, and its subsidiary LLC LENS-Pharm with MNN Poliadenilovaya Kislota + Poliuridilovaya Kislota.
The FAS takes the view that the conduct of this deal could lead to a limiting of access to the market for the sale of these medical preparations by independent counteragent VeroPharm and LENS-Pharm. In light of this, the FAS requires of Sistema and VeroPharm to ensure the fulfillment of all contracts for the delivery of all medicines existing on the date the deal is completed.
Before the deal is done, Sistema is to post on its official website the document regulating its commercial policy as regards VeroPharm medical preparations, and announce changes to commercial policy in letter form to the FAS within thirty days.
The parties are not to, from the date the deal is completed, effect any unfounded economic or technological reduction or halt of the production and supply of goods that are still in demand. They are also to announce to the FAS either of such circumstances in letter form within thirty days.
AFK Sistema and VeroPharm are to annually inform the FAS in letter form that they are meeting these conditions.
The parties to the deal are to announce its completion to the anti-monopoly agency within twenty days from the day the deal is wrapped up.
According to DSM Group data, VeroPharm is third in a rating of the largest Russian pharmaceutical companies. Company product is provided by three plants: in Belgorod, Voronezh, and Pokrov. VeroPharm specializes in the production of Rx medical goods, which account for about 70% of its sales revenues.
Pharmacy Chain 36.6 (RTS: APTK) owns 51.8% of the company.
(Our editorial staff can be reached at firstname.lastname@example.org)
May 27, 2016
Russian Defense Ministry suspects U.S. testing missiles banned by INF Treaty under guise of missile defense tests (Part 2)
Poroshenko calls for tougher sanctions against Russia in conversation with Biden
Russia not bothered by Klimkin's announcement of "Savchenko list" extension - Klintsevich
Sollers recommends 2015 dividend waiver
No plans to expand list of embargoed food products - Tkachev
SOLLERS BOARD RECOMMENDS 2015 DIVIDEND WAIVER - COMPANY
Sberbank not considering participation in RusHydro recapitalization (Part 2)
Observers from CIS, SCO invited to Russia for parliamentary elections, participation of OSCE's ODIHR mission possible
NO EXPANSION OF EMBARGOED FOOD PRODUCTS LIST PLANNED; ONLY EXTENSION OF EFFECTIVE DATE BEING DISCUSSED - TKACHEV
Kyrgyz president urges Armed Forces to be ready to resist any 'dark forces'
VTB boosts stake in Enel Russia to 7.69% (Part 2)
Forty percent of Russians who know about Savchenko's verdict approve of her exchange for Russian citizens - poll
Greek President: Putin's visit to have "exceptionally important implications"